text
stringlengths 0
197k
|
|---|
<|newrecord|> nctId: NCT06353438 id: 2024XXXX briefTitle: Hydraulic Resistance and Older Adults overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-07-31 date: 2024-12-31 date: 2024-04-09 date: 2024-04-09 name: College of Staten Island, the City University of New York class: OTHER name: Bay Ridge Center briefSummary: The goal of this quasi-experimental study using a pre and post test design is to learn about the effect of participating in an exercise program with hydraulic exercise equipment on fall risk in the older adult population. The main questions it aims to answer are:
|
* Does the use of hydraulic exercise equipment decrease fall risk in older adults?
|
* Does the use of hydraulic exercise equipment improve function in older adults?
|
Participants will be evaluated pre and post intervention for strength, fall risk using Berg Balance Scale, Tinetti Balance and Gait Assessment, Timed Up and Go, and functional ability using the Lower Extremity Functional Scale. Participants will engage in an exercise program using 5 different pieces of hydraulic exercise equipment (Frei FACTUM® novus II line) 2x/week for for 6 weeks for 30-45 minutes each session. The equipment uses concentric movements only and works agonist and antagonist muscles with each machine (IE: push and pull, both concentric). conditions: Aging conditions: Fall conditions: Old Age; Debility conditions: Muscle Weakness studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 20 type: ESTIMATED name: Exercise Program measure: Berg Balance Scale measure: Timed Up and Go measure: Tinetti Balance and Gait Assessment Tool measure: Lower Extremity Functional Scale measure: Strength sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bay Ridge Center city: Brooklyn state: New York zip: 11209 country: United States name: Mary Ann Coughlin role: CONTACT phone: 718-306-2924 email: [email protected] lat: 40.6501 lon: -73.94958 hasResults: False
|
<|newrecord|> nctId: NCT06353425 id: 0562/66 briefTitle: Multi-country Survey on Violence Against Women Among Women overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-03 date: 2025-03 date: 2024-04-09 date: 2024-04-09 name: Chulalongkorn University class: OTHER name: Asia and Oceania Federation of Obstetrics and Gynaecology briefSummary: The goal of this observational study is to explore and learn about violence against women (VAW) among reproductive-aged women in Asia and Oceania countries. The main questions it aims to answer are:
|
* pattern and prevalence of VAW among reproductive-aged women
|
* knowledge, attitude, and practice (KAP) towards VAW among reproductive-aged women
|
* the need of support services for VAW among reproductive-aged women
|
Participants will be ever-partnered women aged 15-49 years. The definition of "ever-partnered women" included women who have current and former husbands; current and former cohabiting; or non-cohabiting male intimate partners. conditions: Violence Against Women studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 2000 type: ESTIMATED measure: prevalence of violence against women measure: KAP towards violence against women measure: need of support services for violence against women sex: FEMALE minimumAge: 15 Years maximumAge: 49 Years stdAges: CHILD stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353412 id: treatment methods of IIH briefTitle: Current Treatment Methods of Idiopathic Intracranial Hypertension overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-09-01 date: 2026-03-09 date: 2024-04-09 date: 2024-04-09 name: Assiut University class: OTHER briefSummary: Aim of the study :
|
1. to determine the response to each treatment plan.
|
2. to determine when to choose specific treatment method.
|
3. to determine complication of each type of treatment method conditions: IIH - Idiopathic Intracranial Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 64 type: ESTIMATED name: Lumbar puncture measure: Patient improvement regarding headache, visual symptoms measure: Patients improvement regarding fundus examination during regular visual assessment measure: Complication measure: Other sex: ALL minimumAge: 16 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353399 id: 23.0366 briefTitle: Guided Bone Regeneration With and Without the Use of Intra-marrow Penetrations overallStatus: RECRUITING date: 2023-06-15 date: 2024-06-30 date: 2024-12-31 date: 2024-04-09 date: 2024-04-09 name: University of Louisville class: OTHER briefSummary: The primary aims of this study are to compare, after 6 months, the clinical and histologic results of intra-marrow penetrations vs no intra-marrow penetrations when performing guided bone regeneration procedures. conditions: Ridge Augmentation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The study involves an investigator (surgeon) and an examiner. The examiner measures the clinical parameters before and after surgery and is blinded to the surgical procedure and if intra-marrow penetrations are utilized. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Intra-marrow penetrations name: No Intra-marrow penetrations measure: Alveolar Ridge Width measure: Alveolar Ridge Height measure: Buccal Soft Tissue Thickness measure: Histomorphometric Measurements sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Louisville status: RECRUITING city: Louisville state: Kentucky zip: 40202 country: United States name: Bindu Dukka, BDS, MSD, MPH role: CONTACT phone: 502- 852- 1817 email: [email protected] name: Niti Patel, DMD role: CONTACT phone: 859-685-5423 email: [email protected] name: Bindu Dukka, BDS, MSD, MPH role: PRINCIPAL_INVESTIGATOR lat: 38.25424 lon: -85.75941 facility: University of Louisville status: RECRUITING city: Louisville state: Kentucky zip: 40202 country: United States name: Himabindu Dukka, BDS, MSD role: CONTACT lat: 38.25424 lon: -85.75941 hasResults: False
|
<|newrecord|> nctId: NCT06353386 id: 5684-01A id: MK-5684-01A type: OTHER domain: Merck id: 2023-506288-33 type: REGISTRY domain: EU CT id: U1111-1292-6912 type: OTHER domain: UTN briefTitle: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2028-03-31 date: 2028-03-31 date: 2024-04-09 date: 2024-04-29 name: Merck Sharp & Dohme LLC class: INDUSTRY name: Orion Corporation, Orion Pharma briefSummary: Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).
|
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
|
This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study. conditions: Prostatic Neoplasms, Castration-Resistant studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 220 type: ESTIMATED name: Opevesostat name: Olaparib name: Docetaxel name: Cabazitaxel measure: Number of participants who experience one or more dose-limiting toxicities (DLTs) measure: Number of participants who experience one or more adverse events (AEs) measure: Number of participants who discontinue study intervention due to an AE measure: Prostate-specific antigen (PSA) response rate measure: Objective response rate (ORR) measure: Radiographic progression-free survival (rPFS) measure: Overall survival (OS) measure: Duration of response (DOR) measure: Time to first subsequent anticancer therapy (TFST) measure: Time to pain progression (TTPP) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353373 id: HZKY-PJ-2024-7 briefTitle: Smart Technology Facilitated Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies acronym: SmaVTE-BEST overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2025-02-28 date: 2025-02-28 date: 2024-04-09 date: 2024-04-09 name: Navy General Hospital, Beijing class: OTHER briefSummary: Venous thromboembolism (VTE) is the third leading cause of cardiovascular disease deaths globally, and its incidence is increasing over the years. Hospital-acquired VTE accounts for approximately 75% of all deaths attributed to VTE. However, only half of patients with indications for VTE prophylaxis take preventive measures, and high rates of inappropriate VTE prophylaxis prescribing contribute to the gap between VTE prophylaxis and guidelines. To further minimize the gap between clinical practice and guidelines, a range of strategies have been employed across various fields of VTE prophylaxis. One of the most effective measures is the utilization of a Clinical Decision Support System (CDSS). Smart technology-based CDSS facilitates automated evaluation of VTE risk and detection, addressing issues at both the beginning and end of the in-hospital VTE prevention process. but there is still a lack of research on how to effectively implement evidence-based VTE prophylaxis in the middle of the process.
|
In our hospital, routine use of DeVTEcare system (a CDSS for VTE risk assessment and integrated care) for in-hospital management of VTE has been launched since 2021. This study aims to investigate the effect of integrating bundled guideline-based VTE prevention strategies into the DeVTEcare system on in-hospital VTE prophylaxis. conditions: Venous Thromboembolism conditions: Clinical Decision Support Systems conditions: Digital Health studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 15626 type: ESTIMATED name: Application of the modified DeVTEcare system measure: In-hospital VTE measure: Guideline-compliant prescription of VTE prophylaxis measure: Preventable VTE measure: Hospital-related VTE death measure: Major bleeding measure: Non-major bleeding sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353360 id: HL-06 briefTitle: TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. overallStatus: NOT_YET_RECRUITING date: 2024-04-05 date: 2025-07-15 date: 2026-03-09 date: 2024-04-09 date: 2024-04-09 name: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd class: INDUSTRY briefSummary: The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM). conditions: Glioblastoma Multiforme studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Tumor Treating Fields name: Tislelizumab name: Temozolomide (TMZ) measure: Progression-Free Survival (PFS) measure: Number of participants with adverse events (AEs) measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Overall Survival (OS) measure: PFS rate at 6 months measure: PFS rate at 1 year measure: OS rate at 1-year sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353347 id: HTD1801.PCT106 briefTitle: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin overallStatus: RECRUITING date: 2023-11-13 date: 2025-03 date: 2025-12 date: 2024-04-09 date: 2024-04-18 name: HighTide Biopharma Pty Ltd class: INDUSTRY briefSummary: The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes inadequately controlled with metformin. conditions: Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 555 type: ESTIMATED name: HTD1801 name: Placebo measure: Primary Endpoint: mean change in HbA1c measure: Double-blind (DB) Phase: mean change in fasting plasma glucose measure: DB Phase: mean change in 2-hour postprandial glucose measure: DB Phase: proportion of patients achieving HbA1c <7.0% measure: DB Phase: proportion of patients achieving HbA1c <6.5% measure: DB Phase: mean change in insulin sensitivity (HOMA-IR) measure: DB Phase: mean change in low-density lipoprotein cholesterol (LDL-C) measure: Open-Label Extension (OLE) Phase: mean change in HbA1c measure: OLE Phase: mean change in 2-Hour postprandial glucose measure: OLE Phase: proportion of patients achieving HbA1c <7.0% measure: OLE Phase: proportion of patients achieving HbA1c <6.5% measure: OLE Phase: mean change in insulin sensitivity (HOMA-IR) measure: OLE Phase: mean change in LDL-C sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Baogang Hospital of Inner Mongolia status: RECRUITING city: Baotou country: China lat: 40.65222 lon: 109.82222 facility: Beijing Friendship Hospital, Capital Medical University status: RECRUITING city: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Beijing Luhe Hospital Capital Medical University status: RECRUITING city: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Beijing Pinggu Hospital status: RECRUITING city: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Peking Union Medical College Hospital status: RECRUITING city: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Peking University People's Hospital status: RECRUITING city: Beijing country: China lat: 39.9075 lon: 116.39723 facility: The Second Norman Bethune Hospital of Jilin University status: RECRUITING city: Changchun country: China lat: 43.88 lon: 125.32278 facility: The First People's Hospital of Changde City status: RECRUITING city: Changde country: China lat: 29.04638 lon: 111.6783 facility: Hunan Provincial People's Hospital status: RECRUITING city: Changsha country: China lat: 28.19874 lon: 112.97087 facility: The Third Xiangya Hospital of Central South University status: RECRUITING city: Changsha country: China lat: 28.19874 lon: 112.97087 facility: Chongqing University Three Gorges Hospital status: RECRUITING city: Chongqing country: China lat: 29.56278 lon: 106.55278 facility: The Third People's Hospital of Datong status: RECRUITING city: Datong country: China lat: 40.09361 lon: 113.29139 facility: Nanfang Hospital, Southern Medical University status: RECRUITING city: Guangzhou country: China lat: 23.11667 lon: 113.25 facility: Handan First Hospital status: RECRUITING city: Handan country: China lat: 36.60056 lon: 114.46778 facility: The Fourth Affiliated Hospital of Harbin Medical University status: RECRUITING city: Harbin country: China lat: 45.75 lon: 126.65 facility: Anhui Provincial Hospital status: RECRUITING city: Hefei country: China lat: 31.86389 lon: 117.28083 facility: The Second Hospital of Anhui Medical University status: RECRUITING city: Hefei country: China lat: 31.86389 lon: 117.28083 facility: Hengshui People's Hospital (Harrison International Peace Hospital) status: RECRUITING city: Hengshui country: China lat: 37.73222 lon: 115.70111 facility: Heze Municipal Hospital status: RECRUITING city: Heze country: China lat: 35.23929 lon: 115.47358 facility: Huai'an First People's Hospital status: RECRUITING city: Huai'an country: China lat: 33.50389 lon: 119.14417 facility: Huangshi Central Hospital status: RECRUITING city: Huangshi country: China lat: 30.24706 lon: 115.04814 facility: Huizhou Municipal Central Hospital status: RECRUITING city: Huizhou country: China lat: 23.11147 lon: 114.41523 facility: Huzhou Central Hospital status: RECRUITING city: Huzhou country: China lat: 30.8703 lon: 120.0933 facility: Jinan Central Hospital status: RECRUITING city: Jinan country: China lat: 36.66833 lon: 116.99722 facility: Jingzhou Central Hospital status: RECRUITING city: Jingzhou country: China lat: 30.35028 lon: 112.19028 facility: Jinzhou Central Hospital status: RECRUITING city: Jinzhou country: China lat: 41.10778 lon: 121.14167 facility: The First People's Hospital of Kashgar status: RECRUITING city: Kashgar country: China lat: 39.47066 lon: 75.98951 facility: Hebei Petro China Center Hospital status: RECRUITING city: Langfang country: China lat: 39.50972 lon: 116.69472 facility: Liaocheng People's Hospital status: RECRUITING city: Liaocheng country: China lat: 36.45596 lon: 115.97766 facility: The First Affiliated Hospital of Henan University of Science and Technology (Jinghua) status: RECRUITING city: Luoyang country: China lat: 34.68361 lon: 112.45361 facility: The First Affiliated Hospital of Henan University of Science and Technology (Kaiyuan) status: RECRUITING city: Luoyang country: China lat: 34.68361 lon: 112.45361 facility: Nanjing Drum Tower Hospital - The Affiliated Hospital of Nanjing University Medical School status: RECRUITING city: Nanjing country: China lat: 32.06167 lon: 118.77778 facility: Nanjing First Hospital status: RECRUITING city: Nanjing country: China lat: 32.06167 lon: 118.77778 facility: Nanjing Jiangning Hospital status: RECRUITING city: Nanjing country: China lat: 32.06167 lon: 118.77778 facility: Sir Run Run Hospital Nanjing Medical University status: RECRUITING city: Nanjing country: China lat: 32.06167 lon: 118.77778 facility: The Second Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing country: China lat: 32.06167 lon: 118.77778 facility: The First People's Hospital of Nanning status: RECRUITING city: Nanning country: China lat: 22.81667 lon: 108.31667 facility: The First Affiliated Hospital of Nanyang Medical College status: RECRUITING city: Nanyang country: China lat: 32.99472 lon: 112.53278 facility: Panjin Liaohe Oilfield Gem Flower Hospital status: RECRUITING city: Panjin country: China lat: 41.121 lon: 122.0739 facility: The First Hospital of Qiqihar status: RECRUITING city: Qiqihar country: China lat: 47.34088 lon: 123.96045 facility: Shanghai East Hospital of Tongji University status: RECRUITING city: Shanghai country: China lat: 31.22222 lon: 121.45806 facility: Shanghai Pudong New Area People's Hospital status: RECRUITING city: Shanghai country: China lat: 31.22222 lon: 121.45806 facility: Shengjing Hospital of China Medical University status: RECRUITING city: Shenyang country: China lat: 41.79222 lon: 123.43278 facility: The Sixth People's Hospital of Shenyang status: RECRUITING city: Shenyang country: China lat: 41.79222 lon: 123.43278 facility: Shenzhen People's Hospital status: RECRUITING city: Shenzhen country: China lat: 22.54554 lon: 114.0683 facility: The University of Hong Kong - Shenzhen Hospital status: RECRUITING city: Shenzhen country: China lat: 22.54554 lon: 114.0683 facility: Taihe Hospital status: RECRUITING city: Shiyan country: China lat: 32.6475 lon: 110.77806 facility: Siping City Central People's Hospital status: RECRUITING city: Siping country: China lat: 43.16143 lon: 124.37785 facility: The First Affiliated Hospital of Suzhou University status: RECRUITING city: Suzhou country: China lat: 31.30408 lon: 120.59538 facility: People's Hospital of Tianjin status: RECRUITING city: Tianjin country: China lat: 39.14222 lon: 117.17667 facility: Tonghua Central Hospital status: RECRUITING city: Tonghua country: China lat: 41.71972 lon: 125.92639 facility: The Central Hospital of Wuhan status: RECRUITING city: Wuhan country: China lat: 30.58333 lon: 114.26667 facility: Yijishan Hospital of Wannan Medical College status: RECRUITING city: Wuhu country: China lat: 31.33728 lon: 118.37351 facility: The First People's Hospital of Xiangtan City status: RECRUITING city: Xiangtan country: China lat: 27.85 lon: 112.9 facility: The Affiliated Hospital of Xuzhou Medical University status: RECRUITING city: Xuzhou country: China lat: 34.18045 lon: 117.15707 facility: Yanan University Affiliated Hospital status: RECRUITING city: Yanan country: China facility: Yueyang People's Hospital status: RECRUITING city: Yueyang country: China lat: 29.37455 lon: 113.09481 facility: Yuncheng Central Hospital status: RECRUITING city: Yuncheng country: China lat: 35.02306 lon: 110.99278 facility: The Second Affiliated Hospital of Zhengzhou University status: RECRUITING city: Zhengzhou country: China lat: 34.75778 lon: 113.64861 facility: Affiliated Hospital of Jiangsu University status: RECRUITING city: Zhenjiang country: China lat: 32.21086 lon: 119.45508 facility: Zhumadian Central Hospital status: RECRUITING city: Zhumadian country: China lat: 32.97944 lon: 114.02944 facility: Zhuzhou Central Hospital status: RECRUITING city: Zhuzhou country: China lat: 27.83333 lon: 113.15 facility: Zibo Central Hospital status: RECRUITING city: Zibo country: China lat: 36.79056 lon: 118.06333 facility: The First People's Hospital of Zunyi status: RECRUITING city: Zunyi country: China lat: 27.68667 lon: 106.90722 hasResults: False
|
<|newrecord|> nctId: NCT06353334 id: 2024-3-22-8 briefTitle: Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-12-31 date: 2025-12-31 date: 2024-04-09 date: 2024-04-09 name: Tang Ziren class: OTHER briefSummary: Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain. However, evidence regarding the improvement of neurological function prognosis in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA) by NBP is limited. This study aims to evaluate the safety and efficacy of NBP treatment in improving the neurological function prognosis of patients with ROSC after CA.The study will be a single-center, randomized, double-blind, placebo-controlled trial. The sample size is estimated to be 100 patients. Eligible patients will be randomly allocated in a 1:1 ratio to receive either NBP or placebo treatment daily for a duration of 14 days. The initial administration of NBP or placebo treatment will commence within 6 hours after ROSC following CA. The primary outcome is the proportion of patients with Cerebral Performance Category (CPC) scores of 1-2 at 90 days after randomization in each group. The primary safety outcome is the percentage of severe adverse events occurring during the 14-day treatment period. This trial will determine the efficacy of NBP in providing neuroprotective effects for patients with ROSC after CA. conditions: Butylphthalide conditions: Cardiac Arrest conditions: Neuroprotective Drugs studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Butylphthalide and Sodium Chloride Injection name: Saline Solution measure: The proportion of patients with a CPC score of 1-2 sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Chao-Yang Hospital city: Beijing state: Beijing zip: 100020 country: China name: Xingsheng Wang, M.D role: CONTACT phone: +86 15265386100 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06353321 id: STU-2024-0024 briefTitle: Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-10-01 date: 2025-10-01 date: 2024-04-09 date: 2024-04-09 name: University of Texas Southwestern Medical Center class: OTHER name: RefleXion Medical briefSummary: To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) \[68Ga\]-PSMA-11 PET-CT using Illuccix on the same day. conditions: Prostate Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: PET-CT imaging subsystem of the RefleXion X1 System Device measure: Qualitative assessment of RefleXion X1 imaging performance with Illuccix PSMA PET imaging agent immediately following a standard of care Illuccix PET/CT sex: MALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353308 id: EA230308 briefTitle: Effectiveness of an Online Intervention Using a Feminist Approach on Gender Equality Promotion and Sexual Violence Prevention in China overallStatus: COMPLETED date: 2023-05-12 date: 2024-02-10 date: 2024-03-02 date: 2024-04-09 date: 2024-04-09 name: The University of Hong Kong class: OTHER briefSummary: This paper presents the findings of a clustered randomized controlled trial (cRCT) that evaluated the effectiveness of an online feminist sexual health intervention among Chinese young adults, providing insights into the impacts of this innovative approach and contribute to the growing body of literature on feminist interventions for sexual health and equality promotion. conditions: Sexual Violence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 422 type: ACTUAL name: Sexual Violence Prevention name: Sexual health intervention measure: Rape myth acceptance measure: Sociocultural Attitudes toward Appearance measure: Sexual Attitudes Scale measure: Sexual Desire Inventory sex: ALL minimumAge: 18 Years maximumAge: 29 Years stdAges: ADULT facility: The university of Hong Kong city: Hong Kong zip: 000000 country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
|
<|newrecord|> nctId: NCT06353295 id: 22-38098 id: CO-US-412-6436 type: OTHER_GRANT domain: Gilead Sciences briefTitle: Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study acronym: P4P overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-06 date: 2025-06 date: 2024-04-09 date: 2024-04-09 name: University of California, San Francisco class: OTHER name: Gilead Sciences briefSummary: The overall goal of the P4P: Peers for PrEP (pre-exposure prophylaxis) study is to pilot test a peer-led and delivered intervention for biomedical HIV prevention that is tailored to women who engage in sex work in southwestern Uganda. This study will evaluate whether this intervention is feasible, acceptable, and increases uptake of biomedical prevention. conditions: HIV/AIDS studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A single-arm pilot trial to evaluate a community-based, peer-led and delivered intervention to provide biomedical prevention products (e.g. pre-exposure prophylaxis \[PrEP\] and post-exposure prophylaxis \[PEP\]) for women who engage in sex work in southwestern Uganda. This study will test whether the intervention is feasible, acceptable, and increases biomedical prevention uptake. primaryPurpose: PREVENTION masking: NONE count: 140 type: ESTIMATED name: P4P intervention measure: Uptake of biomedical prevention measure: Feasibility of delivery of the P4P intervention by peers measure: Acceptability of the P4P intervention sex: FEMALE minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Infectious Diseases Research Collaboration city: Kampala country: Uganda name: Jane Kabami, MPH, PhDc role: CONTACT phone: +256 312 281-479 email: [email protected] lat: 0.31628 lon: 32.58219 hasResults: False
|
<|newrecord|> nctId: NCT06353282 id: 24-000795 briefTitle: MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents overallStatus: NOT_YET_RECRUITING date: 2025-07-01 date: 2026-01-31 date: 2026-12-31 date: 2024-04-09 date: 2024-04-09 name: University of California, Los Angeles class: OTHER briefSummary: The primary objective of this study is to determine the safety and feasibility of 3,4-methylenedioxymethamphetamine (MDMA) -assisted psychotherapy to treat resistant post-traumatic stress disorder (PTSD). The secondary objectives are the exploration of effectiveness for treatment-resistant PTSD, symptoms of depression, and anxiety symptoms. conditions: PTSD, Post Traumatic Stress Disorder conditions: Adolescents conditions: Psychotherapy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: MDMA name: Psychotherapy measure: Changes in heart rhythm via Carnation Ambulatory Heart Monitor measure: Changes in blood pressure measure: Change in pulse measure: Change in body temperature measure: Mean change in score of visual analog scale to assess potential for misuse of MDMA measure: Mean change in PTSD symptom severity via the Child PTSD Symptom Scale measure: Mean change in PTSD symptom severity via the Clinician-Administered PTSD Scale (CAPS-CA-5) measure: Mean change in depression symptom severity via the Patient Health Questionnaire-9 (PHQ-9). measure: Mean change in anxiety symptom severity via the Generalized Anxiety Disorder 7-item (GAD-7) sex: ALL minimumAge: 16 Years maximumAge: 17 Years stdAges: CHILD facility: UCLA Semel Institute for Neuroscience and Human Behavior city: Los Angeles state: California zip: 90095 country: United States name: Jessica K Jeffrey, MD, MPH, MBA role: CONTACT phone: 310-825-5263 email: [email protected] name: Marc J Weintraub, Ph.D. role: CONTACT phone: 310-825-1300 email: [email protected] name: Jessica K Jeffrey, MD, MPH, MBA role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 hasResults: False
|
<|newrecord|> nctId: NCT06353269 id: 4255 briefTitle: Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections overallStatus: RECRUITING date: 2024-04 date: 2027-01 date: 2027-10 date: 2024-04-09 date: 2024-04-09 name: University of California, Irvine class: OTHER briefSummary: * The goal of this clinical trial is to learn about medication adherence to difference types of vaginal estrogen in women with low levels of estrogen (for example, post-menopausal women) who have recurrent urinary tract infections. Medication adherence means whether patients take their medicine as prescribed.
|
* Another goal of the study is to learn about changes to the skin of the vagina before and after estrogen treatment, using a specialized imaging modality called optical coherence tomography, which is similar to receiving an ultrasound.
|
* A third goal of the study is to learn about changes to the microbiome (all the bacteria that naturally live in our bodies) before and after treatment with vaginal estrogen. The researchers will be looking specifically at the microbiome in the urine and the vagina.
|
Participants will be assigned by chance (like the flip of a coin) to receive one of three possible vaginal estrogen treatments - cream, tablets, or drug-eluting ring.
|
* The main study tests and procedures include an initial visit in which the researchers will collect baseline information about participants and have participants complete a series of questionnaires.
|
* There will then be 3 and 6 month follow-ups in which the researchers will have participants complete additional questionnaires and the researchers also assess whether participants are using the vaginal estrogen treatment that you were prescribed.
|
If a participant is part of the microbiome cohort, they will also be asked to do the following:
|
* a baseline visit in which urinary and vaginal specimens are collected to assess their baseline microbiome. The vaginal specimen collection will involve a q-tip swab inside the vagina; it is similar to a pap smear.
|
* Finally, participants will have an imaging modality performed on their vagina called optical coherence tomography, which allows the researchers to assess the thickness of the vaginal walls and the blood vessel density. This imaging modality involves the insertion of a thin probe into the vagina to obtain the images of the vaginal wall.
|
* These tests will then be repeated at 6 months to assess if vaginal estrogen treatment causes changes to the vagina. conditions: Recurrent Urinary Tract Infection conditions: Hypoestrogenism studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 111 type: ESTIMATED name: Estring Vaginal Product name: Vagifem name: Estrace 0.01% Vaginal Cream measure: Adherence to vaginal estrogen treatment measure: UTI rates measure: validated patient questionnaire - Urinary Distress Inventory Short Form (UDI-6) measure: validated patient questionnaires - UTI Symptoms Assessment Questionnaire (UTISA) measure: validated patient questionnaires - Treatment Satisfaction with Medications Questionnaire (SATMED-Q) measure: validated patient questionnaires - Patient Global Impression of Improvement Questionnaire (PGI-I) measure: validated patient questionnaires - Medication Adherence Report Scale (MARS-5) measure: optical coherence tomography measurements for nested OCT cohort - vaginal epithelial thickness measure: optical coherence tomography measurements for nested OCT cohort - blood vessel density measure: Vaginal health index for nested microbiome cohort measure: Vaginal maturation index for nested microbiome cohort measure: Urologic microbiome results for nested microbiome cohort measure: Vaginal microbiome results for nested microbiome cohort sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California Irvine Medical Center status: RECRUITING city: Orange state: California zip: 92868 country: United States name: CHARLOTTE TER HAAR role: CONTACT email: [email protected] lat: 33.78779 lon: -117.85311 hasResults: False
|
<|newrecord|> nctId: NCT06353256 id: 300012607 id: UL1TR003096 type: NIH link: https://reporter.nih.gov/quickSearch/UL1TR003096 id: 24POST1198805 type: OTHER_GRANT domain: American Heart Association briefTitle: A Community Health Worker Intervention to Address Preeclampsia acronym: AW2H overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-04-30 date: 2025-04-30 date: 2024-04-09 date: 2024-04-09 name: University of Alabama at Birmingham class: OTHER name: American Heart Association name: National Center for Advancing Translational Sciences (NCATS) briefSummary: United States maternal mortality and preterm birth rates are among the highest among high-income countries due in part to a combination of racial, regional and socioeconomic disparities in access to care and overall health. The research proposed focuses on adapting and expanding a perinatal community health worker intervention for Black postpartum patients with preeclampsia (PE). Investigators will partner with a community-based organization that trains and deploys community health workers. Investigators will test an intervention for urban and rural Black postpartum patients with PE to 1) enhance blood pressure control postpartum and 2) promote long-term cardiovascular disease prevention for this underserved population. This pilot study will determine if randomizing and implementing a community health worker intervention tailored to pregnant people experiencing preeclampsia is feasible and found to be acceptable by participants. conditions: Preeclampsia Postpartum studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: usual postpartum care measure: Acceptability sex: FEMALE minimumAge: 16 Years maximumAge: 56 Years stdAges: CHILD stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353243 id: STUDY00022901 briefTitle: Bilateral Infant Stimulation Study acronym: BLISS overallStatus: RECRUITING date: 2024-02-26 date: 2024-08 date: 2024-08 date: 2024-04-09 date: 2024-04-09 name: Oregon Health and Science University class: OTHER briefSummary: This study will investigate stress that parents of children admitted to the neonatal intensive care unit (NICU) experience. Investigation of a novel intervention of using bilateral alternating stimulation to reduce parental stress and anxiety and increase bonding/attachment in NICU. Evaluate parental stress and feelings of bonding using surveys before and after the intervention. Intervention will be done at neonate's bedside while admitted to the NICU. Vital sign data will be collected as a marker of parent and neonate's stress response during the intervention. conditions: Parent-Child Relations conditions: Preterm Birth conditions: Stress Reaction conditions: Hospitalism in Children studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: Bilateral alternating stimulation measure: Parental anxiety measure: Physiologic stress response measure: Parental distress sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Oregon Health and Science University Neonatal Intensive Care Unit status: RECRUITING city: Portland state: Oregon zip: 97219 country: United States name: Emily Garavatti, MD role: CONTACT phone: 503-494-2634 email: [email protected] lat: 45.52345 lon: -122.67621 hasResults: False
|
<|newrecord|> nctId: NCT06353230 id: 0001 briefTitle: Comparison of Sclerotherapy Agents Used for Rectal Prolapse Treatment in Children acronym: Prolapse overallStatus: COMPLETED date: 2019-10-15 date: 2020-10-14 date: 2021-04-13 date: 2024-04-09 date: 2024-04-15 name: King Edward Medical University class: OTHER briefSummary: Introduction Patients with rectal prolapse are treated with injection sclerotherapy, which is the most often used first-line surgical technique. Injection sclerotherapy has a success rate of 90-100% in youngsters, according to certain studies. Objective To compare the outcome of injection sclerotherapy using 5% Phenol in almond oil, 15% hypertonic saline and 50% dextrose water in the treatment of rectal prolapse in children. conditions: Rectal Prolapse studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Comparison of 5% phenol in almond oil, 15% hypertonic saline and 50% dextrose water for sclerotherapy treatment of rectal prolapse in children. primaryPurpose: TREATMENT masking: NONE maskingDescription: Randomly allocated groupA,B or C by computer generated lottery method.and participants ,care provider and outcome assessor were kept blind by removing the drug name from injection vial count: 93 type: ACTUAL name: injection 5% phenol in almond oil name: injection 15% hypertonic saline name: injection 50% dextrose water measure: Recurrence measure: fecal incontinence sex: ALL minimumAge: 3 Years maximumAge: 13 Years stdAges: CHILD facility: department of pediatric surgery King Edward Medical University city: Lahore state: Punjab zip: 54000 country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False
|
<|newrecord|> nctId: NCT06353217 id: IRB00419034 id: K23DK128572 type: NIH link: https://reporter.nih.gov/quickSearch/K23DK128572 briefTitle: Study of a Primary Care Hypoglycemia Prevention Program overallStatus: RECRUITING date: 2024-04-14 date: 2026-04-14 date: 2026-04-14 date: 2024-04-09 date: 2024-04-10 name: Johns Hopkins University class: OTHER name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: This is a single site, pre-post pilot study. The objective is to evaluate the acceptability and feasibility of a primary care hypoglycemia prevention program for patients taking hypoglycemia-causing medications. The study will also evaluate relevant process outcomes and clinical outcomes for refining the intervention and planning for a larger efficacy trial. conditions: Diabetes Mellitus conditions: Hypoglycemia studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Pre/post pilot study primaryPurpose: PREVENTION masking: NONE count: 35 type: ESTIMATED name: Patient Group (Hypoglycemia Prevention Program) name: Primary Care Physician Group name: Clinic Staff Group measure: Overall acceptability to patients measure: Overall acceptability to primary care providers measure: Overall acceptability to clinic staff measure: Intervention coherence (patients) measure: Opportunity costs (patients) measure: Ethicality (patients) measure: Affective attitude (patients) measure: Burden (patients) measure: Self-efficacy (patients) measure: Perceived effectiveness (primary care providers) measure: Intervention coherence (primary care providers) measure: Opportunity costs (primary care providers) measure: Affective attitude (primary care providers) measure: Burden (primary care providers) measure: Self-efficacy (primary care providers) measure: Burden (clinic staff) measure: Opportunity costs (clinic staff) measure: Recruitment rate measure: Retention rate for second clinic visit measure: Continuous glucose monitoring (CGM) completion measure: Continuous glucose monitoring (CGM) wear time measure: Time needed to complete patient hypoglycemia profile measure: Duration of clinical visit measure: Patient completion of hypoglycemia assessment measure: Primary care provider use of provider hypoglycemia toolkit measure: Patient hypoglycemia burden on continuous glucose monitoring (CGM) measure: Patient time below range on continuous glucose monitoring (CGM) measure: Patient time above range on continuous glucose monitoring (CGM) measure: Patient mean glucose on continuous glucose monitoring (CGM) measure: Patient satisfaction with care measure: Patient activation measure: Patient self-reported hypoglycemic events measure: Changes to hypoglycemia-causing medications measure: Glucagon prescription measure: Continuous glucose monitoring (CGM) prescription measure: Change in Frequency of Referrals to Diabetes Self Management Training (DSMT) measure: Frequency of hypoglycemia history discussions measure: Frequency of Hypoglycemia anticipatory guidance discussions measure: Frequency of Medication adherence discussions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins University School of Medicine status: RECRUITING city: Baltimore state: Maryland zip: 21287 country: United States name: Scott J Pilla, MD, MHS role: CONTACT phone: 908-768-0002 email: [email protected] lat: 39.29038 lon: -76.61219 hasResults: False
|
<|newrecord|> nctId: NCT06353204 id: 3325 briefTitle: Effectiveness of the Justice Diversion Halt-intervention overallStatus: RECRUITING date: 2024-02-01 date: 2027-07 date: 2027-07 date: 2024-04-09 date: 2024-04-09 name: Wetenschappelijk Onderzoek en Datacentrum class: OTHER_GOV name: Utrecht University name: Leiden University briefSummary: In the current study the effectiveness of the Dutch diversion measure Halt is investigated using a randomized controlled trial. Because of the thorough scientific substantiation of the intervention theory, it is hypothesized that receiving the Halt-intervention will lead to less recidivism in comparison to receiving no intervention. conditions: Criminal Recidivism conditions: Delinquency conditions: Antisocial Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A comparison between two groups will be made. One half of the participants will be randomly assigned to a group that receives the Halt-intervention, while the other group receives no Halt-intervention. primaryPurpose: TREATMENT masking: NONE count: 1300 type: ESTIMATED name: Halt-intervention measure: Criminal Recidivism based on self-report measure: Criminal Recidivism based on official police records measure: Criminal Recidivism based on official judiciary records measure: Truancy based on self-report measure: Conventional beliefs measure: Minimizing/mislabeling measure: Social skills measure: Taking responsibility for the consequences of behavior measure: Correct wrongdoing measure: Support from social network measure: Experienced legitimacy measure: Experienced treatment measure: Receiving adequate information measure: The right to be informed measure: Experienced voluntariness measure: Access to legal assistance measure: Knowledge of not obtaining a criminal record measure: Experienced stigmatisation measure: Experienced re-integration measure: Mental health problems during the last six months measure: Experienced problems measure: Delinquent friends measure: Parental involvement measure: Demographical characteristics measure: Halt-intervention program integrity measure: Characteristics Halt-employee measure: Perceived relationship with Halt-employee measure: Educational attainment measure: Type of criminal offense measure: Characteristics of referral to Halt-intervention measure: Types of modules used during the Halt-intervention measure: Parts of the Halt-intervention carries out as group or solo intervention sex: ALL minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: WODC status: RECRUITING city: The Hague state: Zuid-Holland zip: 2500EH country: Netherlands name: Benthe J van Delft, MSc role: CONTACT email: [email protected] lat: 52.07667 lon: 4.29861 hasResults: False
|
<|newrecord|> nctId: NCT06353191 id: 19-002566 id: NCI-2024-00943 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 19-002566 type: OTHER domain: Mayo Clinic in Florida id: P30CA015083 type: NIH link: https://reporter.nih.gov/quickSearch/P30CA015083 id: R01HL169268 type: NIH link: https://reporter.nih.gov/quickSearch/R01HL169268 id: R56HL160643 type: NIH link: https://reporter.nih.gov/quickSearch/R56HL160643 briefTitle: Biomarkers to Predict Cancer Therapy-related Cardiotoxicity overallStatus: RECRUITING date: 2019-05-03 date: 2026-06-01 date: 2026-06-01 date: 2024-04-08 date: 2024-04-08 name: Mayo Clinic class: OTHER name: National Cancer Institute (NCI) name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy. conditions: Hematopoietic and Lymphatic System Neoplasm conditions: Malignant Solid Neoplasm studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Non-Interventional Study measure: Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona status: RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: [email protected] name: Myrah Manuel role: CONTACT phone: 480-574-3157 email: [email protected] name: Lida A. Mina, MD role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: Mayo Clinic in Florida status: RECRUITING city: Jacksonville state: Florida zip: 32224-9980 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: [email protected] name: Pamela Williamson role: CONTACT phone: 904-953-4694 email: [email protected] name: Nadine Norton, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 facility: Mayo Clinic in Rochester status: SUSPENDED city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
|
<|newrecord|> nctId: NCT06353178 id: 20240314 briefTitle: Building Empowerment and Coping Outcomes for caNcer Patients, Survivors and Their Caregivers acronym: BEACON overallStatus: RECRUITING date: 2024-04-08 date: 2025-02-01 date: 2025-04-01 date: 2024-04-08 date: 2024-04-08 name: Color Health, Inc. class: INDUSTRY briefSummary: Cancer has a psychological, emotional and social impact beyond a patient's physical health. This study examines three new online peer mental-wellness support program for cancer patients, survivors or their caregivers. Each program teaches evidence-based skills, in the context of that groups lived experience, to manage the emotional impact of cancer. This study examines the impact of that program. conditions: Cancer conditions: Caregiving Stress conditions: Caregiver Burnout conditions: Survivorship studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized to waitlist or intervention group. Those in intervention group will receive the peer program; those on the waitlist will receive it after being on the waitlist for 3 months. primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: Participants will be notified of a waitlist assignment upon enrolling. Those on the waitlist will receive the intervention after 3 months. count: 120 type: ESTIMATED name: Cancer Connect Program measure: Quality of Life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Color Health status: RECRUITING city: Burlingame state: California zip: 94010 country: United States lat: 37.5841 lon: -122.36608 hasResults: False
|
<|newrecord|> nctId: NCT06353165 id: CRO-2022-12-BAC-SNF-THA-YPZ briefTitle: Anti-bacterial Clinical Study on Teeth, Tongue, Cheek, Gum, and Saliva overallStatus: COMPLETED date: 2023-03-08 date: 2023-04-12 date: 2023-04-12 date: 2024-04-08 date: 2024-04-15 name: Colgate Palmolive class: INDUSTRY briefSummary: This 4-week clinical study was designed to examine the antibacterial efficacy of brushing with a 0.454% stannous fluoride toothpaste with potassium nitrate and pyrophosphate compared to a toothpaste containing 0.76% MFP (marketed as Colgate Cavity Protection Toothpaste) in different regions of the mouth (dental plaque, tongue, cheek, gum surface and in saliva) 12 hours post-brushing (overnight) after 2 and 4 weeks of product use. conditions: Plaque, Dental studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: blinded primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ACTUAL name: Stannous fluoride toothpaste name: Colgate Dental Cream measure: Whole mouth scores of dental plaque measure: Measurement of total bacterial counts on tongue measure: Measurement of total bacterial counts on cheek measure: Measurement of gingivitis measure: Measurement of total bacterial counts in saliva sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: M U International Oral Science Research, Ltd. city: Bangkok state: Krung Thep Maha Nakhon zip: 10250 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
|
<|newrecord|> nctId: NCT06353152 id: GC506-507 briefTitle: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma overallStatus: RECRUITING date: 2023-11-17 date: 2025-11-16 date: 2025-11-16 date: 2024-04-08 date: 2024-04-08 name: Peking University class: OTHER name: Gracell Biopharmaceuticals, Inc. briefSummary: A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma. conditions: Gastric Adenocarcinoma conditions: Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection measure: Occurrence of Dose limiting toxicity. measure: Incidence of treatment-emergent AEs, AESIs, and SAEs. measure: Disease control rate (DCR) measure: Objective response rate (ORR) measure: Duration of disease control (DDC) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Proliferation and persistence of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell measure: Incidence of anti-CAR-T cell antibody in peripheral blood after infusion. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing state: Beijing zip: 100142 country: China name: Shen Lin, Professor role: CONTACT phone: 010-88196561 email: [email protected] name: Shen Lin, professor role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06353139 id: 90591 briefTitle: The Efficacy of Modified Olfactory Training for Patients With Olfactory Dysfunction overallStatus: RECRUITING date: 2023-07-01 date: 2024-12-31 date: 2024-12-31 date: 2024-04-08 date: 2024-04-08 name: Peking University Third Hospital class: OTHER briefSummary: The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are:
|
Is it possible that the device can treat olfactory disorders in adults? Compared to the conventional device, how efficient is the modified olfactory training device for treating patients with olfactory disfunction? conditions: Olfactory Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 72 type: ESTIMATED name: Modified olfactory training device measure: Clinically significant olfactory improvement sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dawei Wu status: RECRUITING city: Beijing state: Beijing zip: 100191 country: China name: Dawei Wu, MD, PhD role: CONTACT phone: 13522503401 email: [email protected] role: CONTACT phoneExt: Wu email: [email protected] name: Dawei Wu, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06353126 id: DTACESALT briefTitle: DEB-TACE Prior to Liver Transplantation in the Treatment of HCC overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-07-01 date: 2027-07-01 date: 2024-04-08 date: 2024-04-08 name: RenJi Hospital class: OTHER name: Boston Scientific Corporation briefSummary: The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to SALT (Sequential Adult Left Lateral Liver Transplantation) can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for SALT receive DEB-TACE 2 weeks prior to the surgery.
|
The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS)；2) Pathological response rate (Pathological Response); 3) Proportion of patients completing SALT; 4) Adverse events related to DEB-TACE. conditions: Liver Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: DEB-TACE measure: Recurrence-free survival (RFS) measure: Overall survival (OS) measure: Pathological response rate (Pathological Response) measure: Proportion of patients completing SALT measure: Adverse events related to DEB-TACE sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353113 id: HS-2023-0254 briefTitle: Feasibility of a Prenatal Yoga Mobile App in African American Pregnant Women overallStatus: RECRUITING date: 2024-04 date: 2024-07 date: 2024-09 date: 2024-04-08 date: 2024-04-08 name: San Diego State University class: OTHER briefSummary: The goal of this research is to test if a prenatal yoga app can improve well-being in African American/Black (AA) pregnant women. The main questions it aims to answer are:
|
1. Is the Down Dog prenatal yoga app feasible for AA pregnant women?
|
2. How does mental and physical health change after using the Down Dog app for 12-weeks?
|
3. What cultural adaptations to the Down Dog app are needed?
|
The study lasts for 12 weeks and participants are asked to:
|
* do prenatal yoga with the app for at least 20 min/day, three days/week, from home
|
* wear a Garmin Vivosmart 5 watch daily
|
* complete four online surveys
|
* complete an optional virtual interview
|
This project aims to advance public health by contributing to a broader understanding of how prenatal yoga can support the health and well-being of AA pregnant women and promote optimal maternal and child health outcomes. conditions: Pregnancy Related conditions: Mental Health Issue conditions: Discrimination, Racial conditions: Stress conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 50 type: ESTIMATED name: Down Dog Prenatal Yoga App measure: Acceptability of the intervention measure: Demand of the intervention measure: Retention measure: Ease of recruitment measure: Discrimination measure: Perceived stress measure: Perinatal Depression measure: Self-awareness measure: Mindfulness measure: Subjective physical activity measure: Objective physical activity (steps) measure: Objective physical activity (intensity) measure: Cardiac health (heart rate) measure: Cardiac health (heart rate variability) measure: Cultural adaptations measure: Birth outcomes (gestational age) measure: Birth outcomes (type of delivery) measure: Birth outcomes (intervention used for delivery) measure: Birth outcomes (birth weight) measure: Birth outcomes (maternal weight) measure: Birth outcomes (pregnancy-related disorders) sex: FEMALE minimumAge: 18 Years maximumAge: 46 Years stdAges: ADULT facility: San Diego State University status: RECRUITING city: San Diego state: California zip: 92182 country: United States name: Jeni Green, PhD role: CONTACT lat: 32.71533 lon: -117.15726 hasResults: False
|
<|newrecord|> nctId: NCT06353100 id: 230602006 briefTitle: Chronic Pain in the General Population of Chile acronym: RDC overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-01 date: 2024-12-30 date: 2024-12-30 date: 2024-04-08 date: 2024-04-08 name: Pontificia Universidad Catolica de Chile class: OTHER name: Chilean Safety Association (ACHS) briefSummary: The present study seeks to follow up the cohort of adults representative of Chile's urban population whose levels of chronic pain were evaluated in March 2023 (baseline) as part of the Mental Health Thermometer (MHT) study. The study consists of a 12 month follow-up telephone interview to assess parameters of chronic pain (CP) and subtypes, mental and physical health, lifestyle and adversity and work characteristics.
|
The study objectives are as follows:
|
1. Estimate the prevalence of CP and subtypes in the general population
|
2. Explore the association between mental health indicators, perceived work stress and presence of CP in the population.
|
3. Investigate the impact of CP (functional, occupational and social) among the subset of participants reporting CP
|
4. Describe the use of management strategies in those who suffer from CP. conditions: Chronic Pain conditions: Migraine Disability conditions: Neuropathic Pain conditions: Fibromyalgia conditions: Depression, Anxiety conditions: Self Harm conditions: Insomnia conditions: Loneliness studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2365 type: ACTUAL measure: Chronic pain (past 3 months) measure: Depression (2 weeks) measure: Anxiety (2 weeks) measure: Migraine Disability measure: Neuropathic Pain measure: Fibromyalgia measure: Self harm (2 weeks) measure: Insomnia (2 weeks) measure: Loneliness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pontificia Universidad Catolica de Chile city: Santiago state: RM zip: 7550139 country: Chile lat: -33.45694 lon: -70.64827 hasResults: False
|
<|newrecord|> nctId: NCT06353087 id: B7451114 briefTitle: Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) acronym: ATTRACT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-11-15 date: 2025-11-15 date: 2024-04-08 date: 2024-04-08 name: Pfizer class: INDUSTRY briefSummary: This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics. conditions: Dermatitis, Atopic conditions: Dermatitis conditions: Eczema conditions: Skin Diseases conditions: Immune System Diseases conditions: Janus Kinase Inhibitors studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Percentage of Participants Achieving >= 75% Improvement From Baseline in Eczema Area and Severity Index (EASI-75) Response at Week 2, 12, 52 measure: Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 2, 12, 52 measure: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 2, 12, 52 measure: Duration of Abrocitinib Treatment: All Participants measure: Demographic and baseline characteristics measure: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 12, 16, 24, and 52 measure: Change From Baseline in Investigator's Global Assessment (IGA) at Weeks 2, 4, 12, 16, 24, and 52 measure: Change From Baseline in Percentage Body Surface Area at Week 2, 4, 12, 16, 24, and 52 measure: Change From Baseline in Patient-Oriented Eczema Measure (POEM) at Week 2, 4, 12, and 52 measure: Change from baseline of Atopic Dermatitis Control Tool (ADCT) score at Week 2, 4, 12, and 52 measure: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score to Week 2, 4, 12, and 52 measure: Change From Baseline in Patient Global Assessment (PtGA) measure: Percentage Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 2, 4, 12, 16, 24, and 52 measure: Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Week 2, 4, 12, 16, 24, and 52 measure: Percentage of Participants Achieving 0 or 1 in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Week 2, 4, 12, 16, 24, and 52 sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353074 id: 1335cemre. briefTitle: Uterine Preservation With Acar's Atony Suture for Postpartum Uterine Hemorrhage overallStatus: COMPLETED date: 2021-01-01 date: 2023-11-30 date: 2023-11-30 date: 2024-04-08 date: 2024-04-08 name: Necmettin Erbakan University class: OTHER briefSummary: This study is aimed to show effectiveness of a new suture technique to stop postpartum uterine bleeding due to uterine atony. conditions: Uterine Atony With Hemorrhage conditions: Postpartum Hemorrhage studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 16 type: ACTUAL measure: Postpartum hysterectomy and/or intensive care unit need ratio sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Cemre Alan city: Konya country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
|
<|newrecord|> nctId: NCT06353061 id: LACC-MET briefTitle: Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-08-01 date: 2026-02-01 date: 2024-04-08 date: 2024-04-08 name: Peking Union Medical College Hospital class: OTHER briefSummary: This is a prospective, single-center, phase II, randomized, window-of-opportunity trial initiated by researchers. The research hypothesis is that metformin can improve the level of hypoxia in locally advanced cervical cancer and further improve progression-free survival. The study aims to compare the improvement of tumor hypoxia with synchronous chemoradiotherapy with or without metformin, using CA-IX PET/CT and radiation positioning spectral CT to evaluate tumor hypoxia, screening hypoxic patients for inclusion in the study, and comparing the effects of synchronous chemoradiotherapy with or without metformin on the degree of hypoxia and progression-free survival in the two groups of patients. conditions: Cervical Cancer conditions: Radiotherapy conditions: Metformin conditions: Hypoxia conditions: PET/CT studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 51 type: ESTIMATED name: Metformin name: Radiotherapy name: Chemotherapy name: PET/CT measure: The degree to which metformin improves the hypoxic index measured by CAIX PET measure: Progression-free survival（PFS） measure: Changes in tumor volume during treatment measure: Hematologic and gastrointestinal toxicities assessed by CTCAE v5.0 measure: Quality of life assessed by QLQ-C30 sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06353048 id: Soh-Med-24-02-04MS briefTitle: Short Term Radiological and Clinical Outcomes of Fixation of Schatzker II Tibial Plateau Fractures by Screws Only Versus Plate and Screws , Comparative Study overallStatus: RECRUITING date: 2024-02-10 date: 2025-02-15 date: 2025-02-15 date: 2024-04-08 date: 2024-04-08 name: Sohag University class: OTHER name: sohag university hospital briefSummary: Tibial plateau fractures are complex injuries produced by high- or low-energy trauma. They principally affect young adults or the 'third age' population ,the tibial plateau is a major weight-bearing surface within the largest and most kinematically complex joint in the human body. Fractures occur as a result of a combination of an axial loading force and a coronal plane (varus/valgus) moment leading to articular shear and depression and mechanical axis malalignment,So Limb alignment and articular surface restoration, allowing early knee motion, are the main goals of surgical treatment.
|
Soft-tissue damage in fractures around the knee is of critical importance. The oedema and inflammation associated with the trauma can easily lead to local venous compromise, dermal hypoxia, and additional soft-tissue injury. This commonly leads to blistering of the skin and in some cases dermal and even muscle necrosis. Blood-filled blisters should be expected to be associated with a worse outcome than clear fluid-filled ones. Management in the early stages of treatment should focus on preventing further soft-tissue injury while waiting to repair the fracture.
|
Traditionally, initial radiograph diagnosis should include anteroposterior (AP), lateral and oblique views. But single radiographs do not allow an exact fragment identification and the initial fracture classification can change in 5% to 24% (mean 12%) of cases and treatment can change in up to 26% of cases after CT scan imaging . These findings and the wider availability of CT scanning have made the oblique views less important in the diagnosis. Intra- and peri-articular soft-tissue structures can be affected even in less complex fracture patterns and some X-ray or CT scan data can also suggest the existence of a lateral or medial meniscal tear. Articular depression \> 6 mm and/or articular widening \> 5 mm are associated with the existence of lateral meniscus, lateral collateral ligament (LCL) or posterior cruciate ligament injuries .
|
Schatzer classification (published in 1974) will be used to complete understanding of the personality of these fracture which is the key element in decision making process when choosing the best possible treatment .
|
In general ,tibial plateau fracture are to be operated on , but the decision whether to be operated or not on a specific fracture should be based on the fracture morphology ,soft tissues , the patient general condition and the expected limb axis and articular surface restoration.
|
Usual indications for surgical treatment are :
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.